SUMMARY Greater use of genetic amniocentesis in the Eastern Ontario region occurred once the results from the various national trials were published.1-3 Acceptance also paralleled an increase in the number of low parity older women having children and the centralisation and greater publicity given to our programme in the late 1970s. A centralised approach has had the positive effects of preventing unnecessary procedures, assuring appropriate patient counselling, follow up, and review, and of increasing obstetric and laboratory expertise. Advanced maternal age has been largely responsible for the increased demand for the service and accounted for an increasing proportion of tests performed, while the absolute number for several other diagnostic categories remained unchanged. We 
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Methods
Only three amniocenteses were carried out in Ottawa before the beginning of the Canadian MRC study in January 1972, which introduced specific data collection forms and the requirement that patients be followed up. The cytogenetic laboratory continued to use these forms after the study ended in 1975, although the data were not always complete. After the programme was centralised in 1979, all procedures were booked through the Division of Genetics and most patients were formally counselled there. New forms were introduced which allowed easy entry of data into a dBase II computer file. One of the participating obstetricians continued to do his own counselling for advanced maternal age (AMA) but used the same forms. Data routinely collected included: gestation at visit and at tap, by dates and by ultrasound, and at delivery; age at delivery, past pregnancy, and family history, and reason for the procedure; and recent radiation, drug, alcohol and smoking history, type of counselling, and Rh status. In addition, information as to whether a tap was attempted, the number of insertions required, the quality and quantity of fluid obtained, placental location, and various laboratory procedures were recorded. Follow up included standard information on pregnancy outcome and complications, birth weight, and the attitude of the patient to the 335 procedure. The reason why a patient who had been counselled declined the test was noted, as was the discovery of a dead fetus at the time of the tap. Starting in 1982, a record was kept of women who declined amniocentesis and counselling when first contacted for an appointment. Cases were summarised and reviewed twice a year. A concerted effort was made at the time of each review to update follow up information, and separate attempts have been made on several occasions to find missing data, including during the course of this review.
Data were analysed using the standard logical search formats of dBase II as well as command programmes normally used for an annual review of the outcome of patients referred to the prenatal programme. For purposes of several comparisons, the data have been divided into pre-1979, 1979 to 1982, and 1983 to 1985 pre-1979, 1979 to 1982, and 1983 to 1985. counselled within the genetics division; one had chronic amniotic fluid leak and a premature labour, one had a failed culture, one felt the wait for the result was too long, one was concerned about the needle and had concern about the possible need for abortion, two gave no reason, and one felt the counselling approach was wrong. Nine women said they would not repeat the procedure (1-I1%) and six Based on the 2645 procedures where information on placental location was recorded, 35-4 posterior, 17-2 anterior (transected by the needle), and 18-4 anterior (not transected) placentas were expected among the 71 tap failures where placental location was adequately documented. However, 25, 25, and 21 respectively were observed (X2 13-9, p<0-005), suggesting that anterior placenta was a risk factor for tap failure. suspected from a previous ultrasound examination (4/27).
RATES OF PREGNANCY LOSS
As already mentioned, the risk of losing the pregnancy was a major concern for women considering amniocentesis and those that had already had a miscarriage often expressed concern that they might be at higher risk. Therefore, we have looked at fetal (5-6%) for those with two previous losses, and 9/62 (14.5%) for those with more than two losses.
Comparing the total loss rate for women with no previous loss to that for women with more than two losses gave a x2 of 5-59 (p>0.025). A question often asked by patients and physicians is whether or not a woman with a history of previous miscarriage has a higher risk from amniocentesis than a woman who has no such history. [35] [36] 45 FIG 3 Totalfetal loss in pregnancy compared by age and previouls history ofpregnancy wastage. Although they do not specifically comment, their data also show the trend to increasing numbers of women over 35 giving birth. This fact, as much as the greater rate of utilisation, has had a major impact on the need to provide resources for genetic amniocentesis. It is not known how long this trend to delayed families will continue, but it is probably reasonable to predict that the rapid increases in demand will end once the 'baby boom' has passed through the 35 and 45 age group. There is nothing yet to suggest a plateau in our rate of utilisation. Our data on gravid status and specific indications follow logically from the increasing numbers of older mothers who have delayed their families. The initial amniocentesis survey2 3 collected data in the early 1970s and had a significantly lower rate of gravida 1 women than in our review. Even among our women seen before 1976, 22-4% were gravida 1.
There are a variety of organisational structures whereby prenatal diagnosis services can be delivered. All aspects of the procedure in Ontario are covered by the universal health care system. The centralised approach has assured that a high level of counselling is provided to the patient, patient satisfaction is high, there is good communication between geneticists and obstetricians, procedures are not performed for inappropriate reasons, and standardised data are maintained which allow for periodic reviews of quality control and statistics. A further advantage is that the laboratory is always aware when a specimen is expected, can plan their workload, and, importantly, can immediately start enquiries if a sample fails to arrive.
Our laboratory has had several years experience with both the flask subculture method and in situ colonial analysis.6 7 As discussed, we believe the latter method has advantages with respect to distinguishing pseudomosaicism and to the number of samples that can be handled per technologist.
As expected, the overall rate of pregnancy loss from the time of referral until delivery increased with maternal age.8 Notably, there was no significant difference in rate for women who had 0, one, or two previous losses, but the rate was higher for those with more than two losses. This is compatible with the data of Warburton and Fraser.9 However, contrary to the recent report by Esrig and Leonardi,'tt we did not find evidence that post-amniocentesis losses were more common in women with a history of miscarriage. The loss rates in the two studies are comparable for those women with no previous pregnancy wastage, but we failed to find a raised rate for those who had had earlier losses. The NICHD study3 also found no difference attributable to a history of previous pregnancy loss.
The women who declined amniocentesis did not differ significantly in age or miscarriage history from those who had amniocentesis, and there was no evidence of a greater fetal loss rate in women who had the test. The loss rate from 17 weeks to term was 9/344 (0-026, 95th confidence interval 0-012 to 0-04) in the 'no tap' group, and 40/2056 (0-019, 95th confidence interval 0-013 to 0-025) in the 'tap' group. From 12 weeks to term the rates and confidence intervals were 0-04 (0-02 to 0-06) and 0-038 (0-03 to 0-046) respectively.
Although we could not show an increased loss rate after amniocentesis, our results suggest that women do associate the procedure with any subsequent spontaneous loss and are less likely to return for another amniocentesis. This is not the case for induced abortion for fetal abnormality.
